Enzyme cascade nanozyme based colorimetric sensor for detection of uric acid as a biomarker of hyperuricemia

Microchimica Acta, Год журнала: 2025, Номер 192(2)

Опубликована: Янв. 15, 2025

Язык: Английский

---

Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study

Metabolites, Год журнала: 2025, Номер 15(1), С. 11 - 11

Опубликована: Янв. 2, 2025

Chronic kidney disease (CKD) is a prevalent global health concern affecting approximately 850 million people worldwide, with significant and rising mortality rate. CKD often coexists hyperuricemia (HSUA), which also increasingly common due to its association hypertension, obesity, diabetes. The interplay between complex; while in vitro studies animal models support role for uric acid mediating glomerular tubule-interstitial damage, HSUA has been shown predict the onset progression of CKD, expectations renal protection by use urate lowering treatment (ULT) are inconsistent. A challenge managing asymptomatic patients lies determining appropriate SUA threshold values. Recent research, including URRAH project, sought identify cut-offs predictive cardiovascular mortality, but these thresholds may vary depending on severity CKD. This variability complicates establishment universal guidelines treating HSUA, leading lack specific recommendations clinical practice. In conclusion, recognized as prognostic factor risk, more research needed refine values benefit from ULT. Stratification based filtration rate be necessary tailor treatments improve outcomes this population.

Язык: Английский

---

U-shaped relationship between uric acid levels and all-cause mortality in patients with hypertension

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 2, 2025

Язык: Английский

---

Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach

Pharmaceutics, Год журнала: 2025, Номер 17(1), С. 102 - 102

Опубликована: Янв. 14, 2025

The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, specific form arthritis. calls for combined curative and preventive management model. A new development in the approach to gout is that NLRP3-targeted biologic agents, such monoclonal therapies, provide more accurate treatment by blocking pro-inflammatory cytokines. Nanoparticle drug delivery enhances biological availability targets, which may increase therapeutic efficacy decrease general toxicity. again cannot be ignored, mainly keeping up certain modifications diet weight, along with pharmacological therapies reduce uric acid (UA) levels frequency acute attacks. advancement genetic profiling patients biomarker discoveries drives trend towards building individualized medicine care, quickly gaining ground most effective method delivering treatments individual patients, moving away from one-size-fits-all treatments. following paper aims an updated account focus on recent developments, order enhance these approaches, quality life standard treatment.

Язык: Английский

---

Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies

Frontiers in Nutrition, Год журнала: 2025, Номер 12

Опубликована: Фев. 7, 2025

Hyperuricemia is associated with several metabolic and cardiovascular disorders, traditional treatments, such as xanthine oxidase (XO) inhibitors, often have limitations, severe hypersensitivity reactions or ineffectiveness in achieving target serum urate levels some patients. Quercetin, a naturally occurring flavonoid, has shown potential hypouricemic agent through XO inhibition. This study aims to evaluate the effect of Quercetin Phytosome™ (QP) supplementation across three cohort studies involving healthy adults various health profiles, exploring its safe, effective intervention for hyperuricemia. Clinical data collected clinics Italy between September 2021 April 2024 under real-life clinical settings from distinct studies, were analyzed. Cohort 1 consisted 164 participants (87 QP-treated, 77 probiotic Streptococcus salivarius (S. salivarius) K12-treated) who monitored 90 days. 2 included 22 mildly hyperuricemic disorders receiving QP, while 3 comprised 64 obese hypercholesterolemia, further divided into moderately QP-treated group (n = 20), Berberine monacolins (BM)-treated 22), normouricemic BM-treated 22). QP was administered at 400 mg quercetin daily all cohorts. Primary endpoints reductions uric acid levels, secondary outcomes effects on lipid profile, glycemia, liver enzymes, treatment tolerability. In 1, significantly reduced by 15.2% males 13.8% females, no significant changes observed group. showed 13.1% reduction (p < 0.01) concurrent 10.2% triglycerides 0.05). 3, led 13.7% decrease 20.8% 0.01), well tolerated cohorts, minimal, transient side effects. demonstrates effect. Additionally, triglyceride-lowering benefits evident, particularly metabolically compromised individuals (Cohorts 3), where these statistically significant. With high tolerability, findings highlight Phytosome™'s safe adjunctive therapy hyperuricemia management, meriting investigation larger, randomized trials confirm efficacy safety. clinicaltrials.gov, identifier NCT06652035.

Язык: Английский

---

Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization

Journal of Inflammation Research, Год журнала: 2025, Номер Volume 18, С. 17 - 30

Опубликована: Янв. 1, 2025

Purpose: Serum uric acid (SUA) is primarily produced through the hydrolysis of purines in liver, with its excretion largely handled by kidneys. Urate transporter 1 (URAT1) inhibitors are known to enhance elimination via kidneys, but they also increase risk kidney stone formation. Currently, xanthine oxidase (XO) predominant uric-lowering medications on market. Methods: In this study, we utilized single-cell RNA sequencing, spatial metabolomics, plasma flow cytometry explore effects Tigulixostat level and hyperuricemic nephropathy (HN) Uox-KO mouse model. Results: discovered that (LC350189) more effectively reduced SUA levels resulted better renal outcomes compared allopurinol, without inducing liver injury urate knockout (Uox-KO) mice. Mechanistically, found improved HN promoting M2 macrophage polarization. Conclusion: These findings suggest as a promising therapeutic option for managing hyperuricemia related conditions. Keywords: nephropathy, Uox-KO, tigulixostat, Single-cell

Язык: Английский

---

Biomimetic bioreactor for potentiated uricase replacement therapy in hyperuricemia and gout

Frontiers in Bioengineering and Biotechnology, Год журнала: 2025, Номер 12

Опубликована: Янв. 7, 2025

Uricase replacement therapy is a promising approach for managing hyperuricemia and gout but hindered by challenges such as short blood circulation time, reduced catalytic activity, excessive hydrogen peroxide (H2O2) production. These limitations necessitate innovative strategies to enhance therapeutic efficacy safety. We designed synthesized RBC@SeMSN@Uri, red cell-coated biomimetic self-cascade bioreactor, which encapsulates uricase (Uri) selenium-based nano-scavenger (SeMSN) within RBC membranes. This design aims reduce immunogenicity, extend systemic circulation, maintain enzymatic activity. In vitro assays were conducted evaluate biocompatibility, anti-inflammatory effects, oxidative stress protection. vivo experiments in models assessed efficacy, biodistribution, biosafety. RBC@SeMSN@Uri effectively degraded uric acid (UA) into allantoin converted H2O2 water, preventing damage inflammation. demonstrated excellent biocompatibility H2O2-induced inflammatory responses compared free uricase. vivo, the bioreactor prolonged significantly levels, alleviated kidney damage, mitigated symptoms of gout. It also targeted inflamed joints, reducing swelling inflammation gouty arthritis models. study presents novel strategy enzyme By integrating membranes, addresses key traditional therapies, offering enhanced stability, superior efficacy. platform holds potential broader applications protein or antibody delivery therapies other diseases.

Язык: Английский

---

The relationship between serum uric acid and accelerated aging in middle-aged and older adults: a prospective cohort study based on CHARLS

The journal of nutrition health & aging, Год журнала: 2025, Номер 29(3), С. 100488 - 100488

Опубликована: Янв. 15, 2025

This study seeks to determine the association between serum uric acid (SUA) and accelerated aging among middle-aged older adults in China, as well assess relationship SUA trajectories risk of aging. We utilized data from China Health Retirement Longitudinal Study (CHARLS), selecting participants who completed follow-ups 2011 2015. Biological age was estimated using Klemera-Doubal method, determined by calculating difference an individual's biological their chronological age. Logistic regression models were employed analyze baseline levels, trajectories, aging, adjusting for potential confounding factors. A total 3,520 (average 59.00 years) included. The results indicated a significant linear positive correlation levels Compared group with lowest those highest had markedly increased (OR = 1.5, 95% CI: 1.23-1.83, P < 0.001). Further longitudinal analysis suggested that maintaining low level associated reduction indicates elevated constitute factor adults. Maintaining at low-level help slow down These findings highlight importance monitoring this demographic, providing scientific basis developing interventions delay

Язык: Английский

---

Spatiotemporal landscape of kidney in a mouse model of hyperuricemia at single‐cell level

The FASEB Journal, Год журнала: 2025, Номер 39(2)

Опубликована: Янв. 16, 2025

Abstract Serum uric acid is an end‐product of purine metabolism. Uric concentrations in excess the physiological range may lead to diseases such as gout, cardiovascular disease, and kidney injury. The includes a variety cell types with specialized functions fluid electrolyte homeostasis, detoxification, endocrine functions. Two‐thirds excreted through kidney, however, exploration markers new therapeutic targets renal tissue hyperuricemia still lacking. Single‐cell spatial omics techniques represent major milestones life sciences. combined measurement physical structure molecular characteristics tissues facilitates pathophysiological processes underlying disease development discovery possible targets. Here, spatiotemporal atlas hyperuricemic nephropathy was investigated using single‐cell RNA sequencing, transcriptomics, proteomics, metabolomics urate oxidase knockout mouse model. Several emerging pathways especially ribosome metabolism related excretion were discovered will be further studies on lowering acid.

Язык: Английский

---

Exploring gene expression, alternative splicing events and RNA-binding proteins changes in PBMC from patients with hyperuricemia

Gene, Год журнала: 2025, Номер unknown, С. 149256 - 149256

Опубликована: Янв. 1, 2025

Язык: Английский

---